Exposição de fibroblastos da cápsula de Tenon normal de portadores de pterígio ao 5-fluorouracil e à mitomicina C

Viveiros, Magda Massae Hata; Schellini, Silvana Artioli; Candeias, J. A. N.; Padovani, Carlos Roberto

doi:10.1590/s0004-27492007000100014

Cited by 6 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Em estudo anterior (5) no qual foi comparada a eficácia do 5-fluo ru racil (5-FU) e da mitomicina C (MMC) sobre a inibição da pro liferação fibroblástica, comprovou-se que ambas as drogas são igualmente eficientes a partir do sexto dia de exposição, com significância estatística. Porém a MMC, por ser um agente alquilante, age inibindo a proliferação de todas as células que porventura tenham entrado em contato com a droga, sejam estas células normais da conjuntiva e córnea adjacentes ou de fibroblastos de pterígios, o que não ocorre com a triancinolona ou o 5-FU.…”

Section: Discussionunclassified

Exposição de fibroblastos de pterígios recidivados e da cápsula de Tenon normal à triancinolona

Viveiros¹,

Kitakawa²,

Carvalho³

et al. 2012

Arq. Bras. Oftalmol.

Self Cite

View full text Add to dashboard Cite

INTRODUÇÃOO receio da recidiva do pterígio após exérese, leva ao uso de medicações adjuvantes. A triancinolona é um corticosteroide potente, de depósito, que atua inibindo a síntese de prostaglandinas e leucotrienos, com consequente efeito anti-inflamatório. Utilizada há anos em vários campos da medicina, a triancinolona é um corticosteroide que vem sendo utilizado na Oftalmologia recentemente, no tratamento de inflamações intraoculares, edema macular associa do à pseudofacia, retinopatia diabética, oclusão de veia central da retina, vasculites retinianas e membrana neovascular sub-retiniana de várias etiologias. Efeitos adversos significativos, tais como, catarata, hipertensão ocular, descolamento de retina e endoftalmite, já foram relatados (1) .Porém, pouco ainda se sabe sobre o uso da triancinolona como medicamento adjuvante no tratamento do pterígio, o que motivou o presente estudo, realizado com o objetivo de avaliar a atividade pro liferativa dos fibroblastos da cápsula de Tenon, provenientes de explantes de pterígios recidivados, em cultura de células, comparando-os com a atividade proliferativa dos fibroblastos da cápsula de Tenon normal, quando expostos à triancinolona. MÉTODOS

show abstract

Section: Discussionunclassified

Exposição de fibroblastos de pterígios recidivados e da cápsula de Tenon normal à triancinolona

Viveiros¹,

Kitakawa²,

Carvalho³

et al. 2012

Arq. Bras. Oftalmol.

Self Cite

View full text Add to dashboard Cite

show abstract

5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence

et al. 2012

View full text Add to dashboard Cite

To compare the efficacy of 5-fluorouracil (5-FU) with mitomycin C (MMC) in preventing pterygium recurrence when used as an adjuvant following pterygium excision with conjunctival autograft. Low-dose MMC combined with conjunctival autograft is an effective treatment for preventing recurrence following pterygium excision, but safety, cost, and availability limit its use in developing countries. There is a paucity of data on the efficacy of 5-FU when used in Africa as an adjuvant to conjunctival autograft following pterygium excision. This is a randomized controlled prospective trial using either 50 mg/ml 5-FU or 0.01% MMC. Eighty eyes of 80 subjects were studied. Forty-six subjects with a mean age 49.8 ± 13.8 years were treated with 5-FU (USD 13.0 per unit), while 34 patients with a mean age 51.9 ± 12.1 years were treated with MMC (USD 20.0 per unit). There was no significant difference in mean age between the two groups (p = 0.48). The ratio of male to female patients in both groups was similar at 0.92:1 for the 5-FU group and 1:1 for the MMC group (p = 0.85). Mean follow-up period was 35.2 ± 29.1 weeks. Recurrence rate in the 5-FU group was 8.7% compared to 11.8% in the MMC group (recurrence risk ratio = 0.71, 95% CI 0.17-3.1, p = 0.7). One patient from the MMC-treated group had corneoscleral melting. Other complications were mild and not sight threatening. In the prevention of pterygium recurrence, 5-FU appears to compare favorably with low-dose MMC when used as an adjuvant following pterygium excision and conjunctival autograft. Further studies are required to assess the long-term effect of using 5-FU in such cases.

show abstract

In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts

et al. 2015

View full text Add to dashboard Cite

To compare the cyclosporine 0.05 % exposure effect on fibroblasts from primary and recurrent pterygium. Primary culture of fibroblasts from primary and recurrent pterygium was performed until the third passage, which was exposed to cyclosporine 0.05 % in a group and the other remaining unexposed (control group), in triplicates. After 3, 6, 12, and 17 days of exposure the viable cell counting was performed by hemocytometer. The results were statistically analyzed using the technique of analysis of non-parametric variance model for repeated measures with three factors. There was a significant reduction in both fibroblast proliferation, in primary as in the recurrent pterygium cultures exposed to cyclosporine when compared not exposed cultures, with statistical significance (P < 0.05). Comparing primary and recurrent pterygium that received the drug, there was no significant difference in cell proliferation in relation to primary or recurrent pterygium. Cyclosporine 0.05 % is effective in inhibiting fibroblast proliferation in culture, both in primary and as in recurrent pterygium.

show abstract

Exposição de fibroblastos da cápsula de Tenon normal de portadores de pterígio ao 5-fluorouracil e à mitomicina C

Abstract: Mitomycin and 5-fluorouracil promote similar inhibition regarding proliferation of normal Tenon's fibroblast cultures.

Cited by 6 publications

References 16 publications

Exposição de fibroblastos de pterígios recidivados e da cápsula de Tenon normal à triancinolona

Exposição de fibroblastos de pterígios recidivados e da cápsula de Tenon normal à triancinolona

5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence

In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts

Contact Info

Product

Resources

About